SUO 2019: Genomic Umbrella Neoadjuvant Study and other Biomarker Trials
SUO 2019 GUNS trial, biomarker trials, high-risk localized prostate cancer, PD-L1 inhibitor, apalutamide, abiraterone, prednisone, docetaxel, niraparib, atezolizumab, improved pCR rates, LHRH antagonists.